ユーザーIDをお忘れですか? or パスワードをお忘れですか?

メニュー 戻る Committee


  • Jonathan  Andrus, MS
    Jonathan Andrus, MS President & COO
    CRIO, United States
  • Matt  Baldwin, MS
    Matt Baldwin, MS Biomedical Data Stewardship Senior Manager
    Amgen, United States
  • Amy  Bertha
    Amy Bertha Executive Director, Regulatory Policy and Innovation
    Bayer, United States
  • Poonam  Bordoloi, PharmD
    Poonam Bordoloi, PharmD Executive Director, Head of Global Medical Affairs Capabilities
    Organon & Co., United States
  • David  Bowers, PharmD
    David Bowers, PharmD Senior Director, Operations
    PPD, United States
  • Philip (P.J.)  Brooks, PhD
    Philip (P.J.) Brooks, PhD Deputy Director, Division of Rare Diseases Research Innovation
    National Center for Advancing Translational Sciences (NCATS), NIH, United States
  • Jennifer  Burgess, MBA, MPH
    Jennifer Burgess, MBA, MPH Vice President, Global Engagement and Communications
    TransCelerate Biopharma Inc., United States
  • Bill  Byrom, PhD
    Bill Byrom, PhD Vice President, Product Intelligence and Positioning; Principal, eCOA Science
    Signant Health , United Kingdom
  • Susan  Callery-D'Amico, BSN
    Susan Callery-D'Amico, BSN Retired, Vice President, R&D Quality Assurance, AbbVie
    United States
  • Meghana  Chalasani, MHA
    Meghana Chalasani, MHA Associate Director for Clinical Trial Innovation, Office of New Drugs, CDER
    FDA, United States
  • Yeh-Fong  Chen, PhD
    Yeh-Fong Chen, PhD Mathematical Statistician (Team Lead), Office of Translational Sciences, CDER
    United States
  • Karla  Childers, MS
    Karla Childers, MS Head, Bioethics-Based Science and Technology Policy
    Johnson & Johnson, United States
  • Deborah  Collyar
    Deborah Collyar President
    Patient Advocates In Research (PAIR), United States
  • Freda  Cooner, PhD
    Freda Cooner, PhD Senior Director - Statistics
    Eli Lilly and Company, United States
  • Stephanie Y. Crawford, PhD, MPH, MS
    Stephanie Y. Crawford, PhD, MPH, MS Professor, Pharmacy Systems, Outcomes and Policy
    University of Illinois at Chicago, United States
  • Sonya  Eremenco, MA
    Sonya Eremenco, MA Executive Director, PRO Consortium
    Critical Path Institute, United States
  • Ron  Fitzmartin, PhD, MBA
    Ron Fitzmartin, PhD, MBA Senior Informatics Advisor, Office of Regulatory Operations, CBER
    FDA, United States
  • David  Fryrear, MS
    David Fryrear, MS Executive Vice President and Head of Quality Assurance
    Astellas, United States
  • M. Scott  Furness, PhD
    M. Scott Furness, PhD Deputy Director, Office of New Drug Products, OPQ, CDER
    FDA, United States
  • William  Gregory, PhD
    William Gregory, PhD Senior Director, Safety and Risk Management
    Pfizer Inc, United States
  • Marianne  Hamilton Lopez, PhD, MPA
    Marianne Hamilton Lopez, PhD, MPA Research Director, Value-Based Payment Reform
    Duke-Margolis Center For Health Policy, United States
  • Sabine  Haubenreisser, PhD, MSc
    Sabine Haubenreisser, PhD, MSc Principal Scientific Administrator, Stakeholders and Communication Division
    European Medicines Agency, Netherlands
  • Jeremy  Jokinen, PhD, MS
    Jeremy Jokinen, PhD, MS Vice President and Head, Safety Evidence and Sciences
    Bristol-Myers Squibb Company, United States
  • Nadina  Jose, MD
    Nadina Jose, MD Assistant Professor, School of Health Professions, MS Clinical Research Program
    Rutgers, The State University of New Jersey, United States
  • Sean D.  Kennedy, MPH
    Sean D. Kennedy, MPH Global Head, Real World Evidence
    ICON plc, United States
  • Agnes  Klein, MD
    Agnes Klein, MD Senior Medical Advisor
    Health Canada, Canada
  • Darryl  L'Heureux, PhD, MPharm, MSc
    Darryl L'Heureux, PhD, MPharm, MSc Director, Clinical Science, Medical Writing, and Publications
    Ambrx, Inc, United States
  • Erik  Laughner
    Erik Laughner Project Manager, Business Operations Staff, OD, CBER
    FDA, United States
  • Rebecca  Lipsitz, PhD
    Rebecca Lipsitz, PhD Senior Director, TA Regulatory Intelligence and Portfolio Policy, Late R&I RA
    AstraZeneca, United States
  • Christopher  Marrone, PharmD, RPh
    Christopher Marrone, PharmD, RPh Outcomes Liaison Advisor – National Accounts, Value, Evidence and Outcomes (VEO)
    Eli Lilly and Company, United States
  • Chris  Matheus, MBA
    Chris Matheus, MBA Chief Commercial and Networking Officer
    Global Life Sciences Alliance (GLSA), United States
  • K. Kimberly  McCleary
    K. Kimberly McCleary Founder and Chief Executive Officer
    The Kith Collective, LLC, United States
  • Ann  Meeker-O'Connell, MS
    Ann Meeker-O'Connell, MS Director, Office of Clinical Policy, Office of Clinical Policy and Programs, OC
    FDA, United States
  • Christine  Moore, PhD
    Christine Moore, PhD Executive Director, Global External Advocacy and Standards
    Organon & Co., United States
  • Jean M. Mulinde, MD
    Jean M. Mulinde, MD Associate Director, Division of Clinical Compliance Evaluation, OSI
    FDA, United States
  • Nobumasa  Nakashima
    Nobumasa Nakashima Health Policy Director, National Healthcare Policy Secretariat
    Cabinet Office, Japan
  • Michael  Neidl, MBA, MS, MSc
    Michael Neidl, MBA, MS, MSc Senior Consultant
    Clinical Research Quality Consultant, United States
  • Anita  Nelsen
    Anita Nelsen Executive Vice President, Translational Medicine
    Parexel, United States
  • David O Olaleye, PhD, MSc
    David O Olaleye, PhD, MSc Senior Manager and Principal Research Statistician
    SAS Institute Inc., United States
  • David J Pepperl, PhD
    David J Pepperl, PhD Senior Consultant and Nonclinical Group Leader
    Biologics Consulting, United States
  • Sissi  Pham, PharmD
    Sissi Pham, PharmD Chief Executive Officer
    AESARA, United States
  • Paul  Phillips
    Paul Phillips Director, Office of Program Operations, OND, CDER
    FDA, United States
  • James E. Polli, PhD
    James E. Polli, PhD Prof, Ralph F Shangraw/Noxell Endowed Chair in Industrial Pharmacy/Pharmaceutic
    University of Maryland School of Pharmacy, United States
  • Margaret  Richards, PhD, MPH
    Margaret Richards, PhD, MPH Executive Director, Solutions
    Panalgo, United States
  • Steven L. Roberds, PhD
    Steven L. Roberds, PhD Chief Scientific Officer
    Tuberous Sclerosis Alliance, United States
  • Khyati  Roberts, RPh
    Khyati Roberts, RPh Retired
    Retired, United States
  • Khushboo  Sharma, MBA
    Khushboo Sharma, MBA Chief Regulatory Innovation Officer
    Accumulus Synergy, United States
  • Nancy  Slater, MBA, PMP
    Nancy Slater, MBA, PMP Senior Director, Portfolio Program Management Therapeutic Area Head
    AbbVie, Inc., United States
  • Nancy Pire Smerkanich, DrSc, MS
    Nancy Pire Smerkanich, DrSc, MS Assistant Professor Regulatory & Quality Sciences
    University of Southern California School of Pharmacy, United States
  • Meredith  Smith, PhD, MPA, FISPE
    Meredith Smith, PhD, MPA, FISPE Senior Director, Implementation Science Pillar Lead
    Evidera, Inc, United States
  • Elizabeth  Somers, MS
    Elizabeth Somers, MS Executive Director, Global Project and Alliance Management
    Merck Sharp & Dohme LLC, United States
  • Evelyn  Soo, PhD, MS
    Evelyn Soo, PhD, MS Director, Bureau of Gastroenterology, Infection and Viral Diseases, HPFB
    Health Canada, Canada
  • Jeffrey N. Stuart, PhD
    Jeffrey N. Stuart, PhD Associate Vice President, Global Regulatory Affairs
    Merck Sharp & Dohme LLC , United States
  • Ling  Su, PhD
    Ling Su, PhD Research Fellow
    Shenyang Pharmaceutical University, Yeehong Business School, China
  • Rachel  Turow, JD, MPH
    Rachel Turow, JD, MPH Managing Counsel, FDA Regulatory
    Walmart, Inc., United States
  • Kristin  Voorhees, MA
    Kristin Voorhees, MA Director, Patient Advocacy
    Ultragenyx, United States
  • Nancy  Watanabe, MS, PMP
    Nancy Watanabe, MS, PMP Independent Consultant
    Independent Consultant, United States
  • Judith  Zander, MD
    Judith Zander, MD Director, Office of Pharmacovigilance and Epidemiology, OSE, CDER
    FDA , United States
Load More